Generic Name: triptorelin
Drug Class: Hormone Therapy Medications
Approval Status: Approved
Generic Version Available: No
Trelstar is a GnRH agonist approved for palliative treatment of advanced prostate cancer.
Testosterone and other male hormones (androgens) stimulate prostate cancer growth. Gonadotropin-releasing hormone (GnRH) agonists, also known as luteinizing hormone-releasing hormone (LHRH) agonists, block signals in the brain that direct the testicles to produce testosterone. Testosterone levels go up briefly (known as a flare) before falling to very low levels.
Dosing Info: Trelstar is given as a long-acting intramuscular injection that lasts from one to six months, depending on the dose.
Common side effects include hot flashes, bone pain, headache and swelling. Medications that lower testosterone may lead to reduced sexual desire, erectile dysfunction and shrinkage of the testicles. Potential serious side effects include increased risk of diabetes and cardiovascular disease.
For More Info: http://www.trelstar.com/
Co-Pay Program Info: http://www.trelstar.com/access-and-resources
Patient Assistance Program Info: http://www.trelstar.com/access-and-resources
Last Reviewed: September 19, 2018